A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
G
Greg Durm, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
1
2 Locations
Brief description of study
To assess the safety and tolerability of TTX-080
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: tumor
-
Age: 18 years - 100 years
-
Gender: All
Updated on
03 Apr 2025.
Study ID: CTO-TTX-080-001, 12189, TX11413
